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Introduction. Current knowledge about colorectal cancer (CRC) identifies tumor immunogenicity as one of the more 
important issues. In cancers, a prerequisite for immune system activation is the presentation of tumor associated antigen 
(TAA) epitopes to immunocompetent cells. HLA-A2 is one of the antigens in the context of which TAAs are present, but 
data on the possible impact of HLA-A2 antigen expression on the survival of patients with colorectal cancer are scarce and 
sometimes contradictory. The aim of this study was to analyse the relationship between HLA-A2 expression in patients 
with left-sided colorectal cancer in various stages of disease and their long-term survival, and to answer the question of 
whether a lack of HLA-A2 expression is actually a negative prognostic factor.
Material and methods. A prospective analysis of 58 patients with left-sided colorectal cancer was carried out. Expression 
of HLA-A2 was determined by patient blood lymphocyte staining, and analysed using flow cytometry.
Results. In the study group, patients with HLA-A2 expression lived statistically longer than HLA-A2 negative patients 
(p = 0.027). There was no significant difference in overall survival between the HLA-A2+ and HLA-A2- groups with stage II 
and III left-sided CRC. However, the Cox proportional hazard model showed that a lack of HLA-A2 expression was a negative 
prognostic factor in the group of radically operated patients without distant metastases.
Conclusions. HLA-A2 status may affect the clinical course of patients with left-sided colon and rectal cancer, although 
left-sided tumors are less immunogenic than right-sided ones. HLA-A2-positive patients with left-sided colorectal cancer 
lived statistically longer than those who were HLA-A2-negative (p = 0.027). Lack of HLA-A2 expression was a negative 
prognostic factor in the group of radically operated patients.
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Introduction
The appropriate immune response to tumor cells is depen-
dent on their ability to be recognized by immunocompetent 
cells. Tumor associated antigens (TAA), or their epitopes, are 
presented by antigen presenting cells (APCs) in the context of 
human leukocyte antigen (HLA) expression. Some TAA-derived 
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chromosomally instable (CIN) phenotype located in the left 
side of the colon and rectum) [22]. This heterogeneity should 
be used to stratify patients in order to provide them with the 
most optimal, current, and novel immune-based therapeutic 
strategies available in clinical practice [21].
In this study, we concentrated on tumors located in the left 
colon and rectum – a more homogenous sub-group of CRC. 
Locally advanced malignancies were the main area of interest.
The aim of this study was to answer the question of wheth-
er HLA-A2 expression is an important prognostic factor in 
left-sided CRC, which may present with decreased immuno-
genicity compared to right-sided CRC. 
Material and methods
The study group consisted of 58 colorectal cancer patients 
treated in a single institution between 2007 and 2012. Only 
patients with tumors located in the rectum or left colon were 
included. The term left colon was defined as the large intestine, 
from the left 1/3 of the transverse colon distally. All patients had 
histologically confirmed disease, were over 18 years-old, and had 
had an electively performed surgical procedure. Patients with 
simultaneous right-sided colon cancer or patients with a history 
of other neoplastic diseases were excluded. Preoperative radio-
therapy was used in 3 of the rectal cancer patients. All patients 
had no history of autoimmune diseases or recent infections. The 
group was composed of 25 women and 33 men, with a mean 
age of 66 (SD 11), in varying stages of disease (tab. I).
The surgical procedures were carried out according to 
oncological guidelines. Due to the changes of the TNM staging 
systems during the study period, all the specimens were re-
-staged according to the 7th edition of the TNM. The clinical 
and pathological data were recorded. Patients received posto-
perative chemotherapy if indicated. All patients were followed 
up for at least 5 years, or until death, and dates of death were 
verified by the census registry office. 
All patients provided their informed, written consent. The 
study was approved by the Jagiellonian University Ethical Com-
mittee KBET no. 86/B/2007 and KBET no. 122.6120.128.2015. 
The study was registered at ClinicalTrials.gov, registration num-
ber NCT03640572.
Blood samples were collected prior to any interventional pro-
cedure in sterile EDTA vacutainers. Cell preparation was started 1–2 
hours after a blood draw. Expression of HLA-A2 was determined by 
patient blood lymphocyte staining, using PE-conjugated mouse 
anti-human HLA-A2 mAb or PE-conjugated isotype-matched 
mouse immunoglobulins (both BD Pharmingen) as a negative 
control, followed by lysis of erythrocytes (FACS Lysing Solution, BD 
Biosciences) and flow cytometry analysis (FACS Canto). 
Statistics
The statistical analysis was conducted using the software Sta-
tistica 13 (StatSoft Inc.). The Kaplan-Meier method was used 
for the calculation of survival probabilities and the Wilcoxon- 
epitopes require a specific HLA, or other antigens, for presen-
tation. HLA class I antigens are integral membrane glycopro-
teins that are inherited and expressed at varying levels on the 
surface of virtually all somatic cells [1]. It is known that HLA-A2 
(MHC class I) is common among Caucasians (approximately 
45% of the Caucasian population) [2] and that some antigens 
characteristic for colorectal cancer (CRC) are presented in its 
context. These include CSNK1A1, GAS7, HAUS3, SRPX, WDR46, 
ERBB2, AKAP13, and MUC1 antigens. 
A large proportion of cancer vaccine research has been 
limited to the HLA-A2-positive population, and HLA-A2-ne-
gative patients have been used as a control group in targeted 
immunotherapy studies [3]. However, some findings show 
that HLA status itself can influence the clinical course of the 
disease, as the natural immune response may differ between 
patients with or without this antigen expression.
Many studies have described HLA expression in patients with 
cancers of the head and neck [4], breast [5], ovary [6, 7, 8], prostate 
[8], primary laryngeal squamous cell cancers [9], non-small cell 
lung cancer [10], melanoma [1], as well as on tumor cells. 
Data on the possible impact of HLA-A2 antigen expression 
on the survival of patients with colorectal cancer are limited 
and sometimes contradictory. Most data covers a mixed pop-
ulation of right and left-sided colon and rectal cancer patients. 
Since we know that MHC class I expression is often absent 
in micro-satellite instability (MSI) tumors [11, 12], which are 
clinically characterized as having a favorable prognosis and 
are more frequently observed in right-sided colon tumors [13, 
14], the results obtained from a mixed population of all colon 
and rectal cancer patients might not be representative [15]. 
According to UICC cancer statistics published in 2018, colo-
rectal cancer is the 3rd cancer in terms of incidence and second 
in cancer-related mortality in the world. Despite progress in 
prevention and therapy, there is still space for new therapies 
and translational research in colorectal cancer. In recent years, 
several trials on immunotherapy using checkpoint inhibitors 
in colorectal cancer have produced promising results [16]. Ho-
wever, more than 50–80% of cancer patients fail to respond to 
checkpoint inhibitor therapy [17]. Therefore, the investigation 
of predictive and prognostic factors in various subgroups of 
colorectal cancer patients is justified.
Colorectal cancer is not a homogenous disease in terms of 
primary tumor location, and there is evidence that right-sid-
ed and left-sided cancers may have different biologies and 
prognoses [18–21]. CRC immunogenicity, understood as the 
ability to induce an immune response, also differs between the 
right and left sides of the colon. There are two different types 
of colorectal cancer – those which are highly immunogenic 
(with multiple DNA mutations, chromosomal stability (CS), 
microsatellite instability (MSI) phenotype and the presence of 
multiple tumor-infiltrating lymphocytes (TILs), prevalent in the 
right colon) and those with low immunogenicity (with a limited 
number of DNA mutations, a microsatellite stable (MSS) and 
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Table II. Clinicopathological characteristics of patients in HLAA2+ and 
HLAA2- groups
HLAA2+    
n = 33
HLAA2–     







Gender M/F 21/12 12/13 0.234
T1 0 0 >0.05*
T2 5 4 0.930
T3 27 12 0.007
T4 1 9 0.001
N- 15 10 0.678
N+ 18 15 0.678
M0 28 18 0.232
M1 5 7 0.232
Stage I 4 3 0.989
Stage II 11 7 0.664
Stage III 13 8 0.562
Stage IV 5 7 0.232
Left colon 20 7 0.014
Rectum 13 18 0.014
G1 10 7 0.847
G2+G3 23 18 0.847
-Gehan test for the comparison of survival curves between 
groups. The Cox proportional hazard model was used for mul-
tivariate analysis. The Chi-square test and the Fisher exact test 
were used to compare the clinical and pathological features 
between the HLA-A2-positive and negative groups. Mean 
patient age was compared using Mann Whitney’s U test. A p-
-value of < 0.05 was established as statistically significant.
Results
Fifty-eight colorectal cancer patients were evaluated; 33 were 
found to be HLA-A2-positive (56% of whole study group). The 
distribution of clinicopathological characteristics of patients in 
HLA-A2+ and HLA-A2- groups are listed in table II. 
The groups of patients with the presence or absence of 
HLA-A2 had similar structures in terms of age, gender, grade 
of differentiation (G), and TNM, and differed significantly only 
in terms of their T3 and T4 characteristics and location (left 
colon/rectum).
The analysis of clinicopathological features showed that 
in the group of patients with T3 tumors, patients with HLA-A2 
expression predominated, while in the group of patients with 
T4 tumors most patients were HLA-A2-negative.
Among the patients with rectal tumors, the HLA-A2- 
-negative phenotype dominated, while among patients with 
left-sided colon tumors, significantly more patients had HLA-A2 
expression.
All the patients were followed-up for at least five years.
The 5-year survival rate for HLA-A2-positive patients in all 
stages was 72.7%, while for HLA-A2-negative patients it was 
40% (fig. 1).
The Kaplan Meier plot (fig. 1) showed that in the entire 
study group HLA-A2-positive patients lived longer then 
Table I. Clinicopathological characteristics of the patients

























HLA-A2-negative ones. This difference was statistically signifi-
cant (p = 0.027) according to the Wilcoxon-Gehan test.
Therefore, in our patient cohort, we found that the expres-
sion of HLA-A2 was associated with prolonged survival. In 
a group consisting of stage II and III CRC analyzed together, the 
5-year survival rates were 75% and 36% for HLA-A2-positive and 
HLA-A2-negative patients respectively. The difference between 
the groups however was not statistically significant (fig. 2). 
An analysis of the prognostic factors in locally advanced 
cancer was performed. 
Variables with confirmed prognostic value, such as tumor 
stages I–III, radicality of resection, as well as HLA-A2 status were 
included in the Cox proportional hazard model. 
HLA-A2 status was an independent prognostic factor in 
this group of patients (p = 0.012; HR = 2.65; with 95% CI for 
HR: 1.23–5.72). This finding showed that the lack of expression 
of HLA-A2 was an independent negative prognostic factor.
Discussion
The results from this study show that the presence of HLA-A2 
in patients with left-sided colon and rectal cancers is an im-
portant prognostic for their outcomes. HLA-A2 is among the 
8 most frequent HLA alleles (HLA A*01, A*02, A*03, A*24, B*07, 
B*08, B*44, C*07) in the Caucasian population [23]. In our study, 
the expression of HLA-A2 was observed in 56% patients with 
CRC. This percentage is slightly higher than the prevalence of 
HLA-A2 antigens in the Caucasian population in Central and 
Western Europe, which is around 45% (42.6-51.3%), and also 
higher than in the results of the study by Kiewe et al. who found 
a frequency of exactly 50% of HLA-A2 expression. [2] However, 
these findings are not statistically significant. 
The groups of patients with the presence or absence of HLA-
-A2 expression had similar structures in terms of age, gender, 
grade of differentiation (G) and TNM, and differed significantly 
only in terms of T3 and T4 characteristics and location (left colon, 
rectum).  These patients were not preselected, and the researchers 
were not aware of their HLA status during patient recruitment. 
The location of tumors does not influence survival, be-
cause, as previously mentioned, rectal and left-sided colon 
cancer patients have very similar prognosis. Moreover, only 
3 rectal cancer patients received pre-operative radiotherapy 
(two HLA-A2-negative and one HLA-A2-positive). The depth 
of the invasion itself, the T feature, is not a potent prognostic 
factor until the tumor cannot be radically resected. In order 
to overcome the imbalance in the above mentioned features, 
a multivariate proportional hazard model was constructed.   
In our analysis, there was a significantly higher survival 
rate for HLA-A2-positive patients, with 72.7% 5-year survival 
for the HLA-A2-positive patients and 40% for HLA-A2-negative 
patients. The difference between these groups was found to 
be statistically significant (p = 0.027). 
Our results conflict with the study by Kiewe et al. who 
found no statistically significant difference in 5-year survival 
and overall survival between HLA-A2-positive and HLA-A2- 
-negative groups of patients with colorectal cancer [2]. One 
possible explanation for these differences might be differences 
in the patient cohort. 
In the group of patients with locally advanced cancer 
after radical surgery, the lack of expression of HLA-A2 was an 
independent prognostic factor which negatively affected sur-
vival (p = 0.012; HR = 2.65; with 95% CI for HR: 1.23–5.72). This 
phenomenon is not observed in all cancers. In breast cancer, 
HLA positive status is a favorable prognostic factor, however, 
in ovarian cancer it is a negative prognostic factor [7].
The 2015 Consensus of Molecular Subtypes (CMS) is consi-





























































Figure 1. Cumulative proportion of survival for left-sided colorectal 
cancer patients in all tumor stages in HLAA2+ and HLAA2– groups
Figure 2. Cumulative proportions of survival for HLA-A2+ and HLA-A2– 
groups of left-sided colorectal cancer patients – tumor stages II+III
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for CRC – with clear biological interpretability – and a basis 
for future clinical stratification and subtype-based targeted 
interventions. This study identified 4 consensus molecular 
subtypes: CMS1 (MSI-immune), CMS2 (canonical), CMS3 (meta-
bolic), CMS4 (mesenchymal) [24]. In relation to the anatomical 
location of CRC, CMS1 dominates in the right colon, CMS2 
in the left colon, and CMS3 and CMS4 tumors do not have 
a specific anatomic location.
The group of patients in our investigation was more homo-
genous than in other studies, as only left-sided colon and rectal 
cancer patients were included. Earlier studies analyzed a mixed 
population of colorectal [2, 25, 26], colon [27], or only rectal can-
cer patients [15, 28]. The authors of previously published papers 
did not take into account the fact that colorectal cancer may 
differ in biology, and thus the prognosis and response to treat-
ment may vary, depending on the location of the tumor [18–21].
HLA-A2 expression is investigated in patients in several 
ways. One of the approaches uses the identification of HLA-A2 
on the surface of cancer cells, other approaches identify its 
expression on somatic cells.
In publications, HLA status is mostly characterized in terms 
of the tumor environment, and its involvement in the evasion 
of the immune response, by analysis of its expression by the 
immunohistochemistry in tumor-infiltrating immune cells or 
in tumor cells. On the other hand, HLA status is detected in 
host peripheral blood cells, reflecting its role in the recogni-
tion of tumor antigens, by identifying the HLA protein using 
techniques such as immunoassays, flow cytometry etc., or the 
gene alleles, mainly by polymerase chain reaction (PCR) [10]. 
The interpretation and comparison of studies examining 
HLA class I antigen expression are generally very difficult, be-
cause the methods used for the analysis of HLA class I antigen 
expression vary substantially [29]. According to a recently pub-
lished study, exposure to an inflammatory environment might 
be responsible for upregulating HLA class I gene expression in 
tumor cells, but the presence of HLA class I molecules at the 
cell surface is precluded by defects in other components of 
the antigen processing machinery. Besides, RNA expression 
analysis can detect HLA class I not only in tumors but also in 
immune and other stromal cells expressing this HLA. Therefore, 
HLA class I phenotypes should be supported by genetic data 
confirming mechanistic defects, while RNA expression level 
appears insufficient to determine HLA class I tumor status [30]. 
Although there are some studies assessing HLA-A on CRC 
tumor surface in the available literature [15, 25–28, 30], HLA-A2 
expression on somatic cells in patients with CRC has not been 
extensively studied in the past [2]. 
In this study we decided to determine HLA-A2 expression on 
somatic cells from the peripheral blood, and therefore, it is very 
difficult to compare our findings with those of other studies. It 
would be interesting to assess HLA-A2 expression on somatic 
and cancer cells simultaneously, but unfortunately this was not 
possible due to organizational and financial constraints.
Tumor cells do not present distinctly different HLA class I 
antigens than the host cell, however, it should be noted that 
one mechanism of cancer escape from the control of the 
immune system is the loss, or reduction, of the expression of 
HLA class I antigens on cancer cell surfaces. Therefore, tumor 
cells may differ from somatic cells in this respect. The loss 
of HLA class I is rather rare (16–20%) among MMR-p (MSS) 
tumors which dominate in the left half of the colon, which 
was confirmed on a larger cohort by Ijsselsteijn et al. [30]. The 
conclusion from their study, that HLA class I is an important 
determinant of metastatic homing in CRCs, is in-line with our 
observation of better prognosis for patients with left-sided 
colorectal cancer and HLA-A2 expression.
Recently, Löffler et al. [23] provided comprehensive data 
on the HLA presented antigenic repertoire of CRC cells. They 
identified a set of 758 HLA class I and 310 HLA class II present-
ed peptides (ligandome), exclusively expressed on colorectal 
carcinoma tissue, and proposed 12 naturally presented HLA 
class I ligands out of 38 preselected peptides (five peptides 
each were selected for the seven most frequent HLA allotypes 
in the Caucasian population and three additional peptides 
were selected for HLA-C*07), as putative candidates for future 
anti-CRC vaccination. Although among them only one HLA-A2 
was presented, one cannot exclude the possibility that other 
non-selected peptides, including those related to HLA-A2, may 
be effective in the induction of an adaptive anti-tumor immune 
response, thus increasing the survival of HLA-A2 positive pa-
tients. Still more translational studies should be performed in 
order to understand CRC and immune system interactions.
Conclusions
In summary, the results of our study show that:
1. Patients with left-sided colorectal cancer and HLA-A2 ex-
pression lived statistically longer than HLA-A2-negative 
patients. 
2. Lack of HLA-A2 expression was a negative prognostic factor 
in the group of patients with radical resections without 
metastases.
3. HLA-A2 status may affect the clinical course of patients 
with left-sided colon and rectal cancer, even though these 
tumors are considered less immunogenic than right-sided 
cancers.
The question remains whether we should consider the 
status of HLA-A2 expression when qualifying patients for adju-
vant treatment and choosing between more or less aggressive 
therapies to improve their treatment results.
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